The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Official Title: Phase II Study of Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
Study ID: NCT02318784
Brief Summary: The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
Detailed Description: Neuroendocrine malignancies such as pancreatic neuroendocrine tumors (PNETs) and gastrointestinal (GI) carcinoids, are generally rare but their incidences are increasing. In vitro and in vivo studies have shown that proteasome inhibitors have activity against a variety of tumor types. Carfilzomib (Kyprolis®) is an irreversible proteasome inhibitor with a favorable safety profile that has been studied in a variety of hematologic and solid tumors. Carfilzomib received accelerated approval from the U.S. FDA in 2012, based on a favorable response rate, for the treatment of patients with multiple myeloma who received at least two prior therapies, and demonstrated disease progression within 60 days of completing the last therapy. In this multi-center study, the investigators propose to evaluate carfilzomib for the treatment of patients with advanced neuroendocrine cancers.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Rocky Mountain Cancer Center, Denver, Colorado, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Florida Hospital Cancer Institute, Orlando, Florida, United States
Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
Ingalls Cancer Research Center, Harvey, Illinois, United States
Research Medical Center, Kansas City, Missouri, United States
Oncology Hematology Care, INC., Cincinnati, Ohio, United States
Spartanburg Regional Medical Center/Gibbs Cancer Center, Spartanburg, South Carolina, United States
Tennessee Oncology PLLC, Nashville, Tennessee, United States
Center for Cancer and Blood Disorders, Fort Worth, Texas, United States
Name: David Spigel, M.D.
Affiliation: SCRI Development Innovations, LLC
Role: STUDY_CHAIR